Mizuho Cuts Lantheus (NASDAQ:LNTH) Price Target to $115.00

Lantheus (NASDAQ:LNTH) had its target price decreased by Mizuho from $120.00 to $115.00 in a research note released on Wednesday morning,Benzinga reports. Mizuho currently has an outperform rating on the medical equipment provider’s stock.

LNTH has been the topic of a number of other research reports. Wall Street Zen cut Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Citizens Jmp reiterated a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a research report on Monday, June 29th. Truist Financial boosted their price target on shares of Lantheus from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Finally, Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $109.71.

Lantheus Stock Down 1.3%

Shares of NASDAQ LNTH opened at $99.64 on Wednesday. Lantheus has a 12 month low of $47.25 and a 12 month high of $111.86. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $6.49 billion, a price-to-earnings ratio of 24.01 and a beta of -0.06. The business has a 50-day moving average of $103.99 and a 200-day moving average of $86.74.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same period last year, the firm posted $1.53 earnings per share. Lantheus’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts expect that Lantheus will post 4.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Institutional investors have recently added to or reduced their stakes in the company. M&T Bank Corp purchased a new position in shares of Lantheus in the fourth quarter valued at about $370,950,000. Farallon Capital Management LLC boosted its holdings in shares of Lantheus by 56.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after purchasing an additional 1,950,252 shares during the period. Reinhart Partners LLC. grew its stake in shares of Lantheus by 2.2% in the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after purchasing an additional 34,501 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Lantheus by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after purchasing an additional 44,374 shares during the last quarter. Finally, Carmignac Gestion increased its holdings in Lantheus by 18.4% during the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock valued at $100,729,000 after purchasing an additional 206,000 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.